<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematological diseases</z:e> such as <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e>) or <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), some abnormalities in the chemiluminescence of neutrophils are observed </plain></SENT>
<SENT sid="1" pm="."><plain>There are two groups; one includes <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>), <z:e sem="disease" ids="C0040028" disease_type="Disease or Syndrome" abbrv="">essential thrombocythemia</z:e> (ET) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, which <z:hpo ids='HP_0000001'>all</z:hpo> have decreased chemiluminescence of neutrophils </plain></SENT>
<SENT sid="2" pm="."><plain>The other group includes <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e>) which has increased neutrophil chemiluminescence </plain></SENT>
<SENT sid="3" pm="."><plain>We studied the neutrophil function by analyzing the chemiluminescence in 35 patients with <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematological diseases</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>In most of these cases the defects in chemiluminescence in 35 patients with <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematological diseases</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>In most of these cases the defects in chemiluminescence in response to <z:chebi fb="0" ids="53490">N-formyl-L-methionyl-L-leucyl-L-phenylalanine</z:chebi> (<z:chebi fb="0" ids="53490">FMLP</z:chebi>) were correlated with those in response to <z:chebi fb="0" ids="8116">phorbol</z:chebi> 12-<z:chebi fb="0" ids="30807">myristate</z:chebi> 13-<z:chebi fb="49" ids="30089,47622">acetate</z:chebi> (<z:chebi fb="1" ids="53780">PMA</z:chebi>) </plain></SENT>
<SENT sid="6" pm="."><plain>But there were exceptional cases in which the maximal light emission of chemiluminescence (Max CL) in response to <z:chebi fb="0" ids="53490">FMLP</z:chebi> was obviously lower than controls despite the fact that the Max CL in response to <z:chebi fb="1" ids="53780">PMA</z:chebi> was the same as the controls </plain></SENT>
<SENT sid="7" pm="."><plain>These facts suggest a heterogenicity of the defect site in these diseases </plain></SENT>
<SENT sid="8" pm="."><plain>There was a correlation between the level of chemiluminescence and the neutrophil alkaline phosphatase (NAP) activity in these patients </plain></SENT>
<SENT sid="9" pm="."><plain>In vitro culture of <z:mp ids='MP_0005481'>CML</z:mp> neutrophils with granulocyte colony-stimulating factor (G-CSF) showed a correlation between the increase in the level of chemiluminescence and NAP activity </plain></SENT>
<SENT sid="10" pm="."><plain>These results suggest that NAP may take part in the control of neutrophil function </plain></SENT>
</text></document>